IL145894A0 - Use of heparin-binding antagonists in the inhibition of bradykinin release - Google Patents
Use of heparin-binding antagonists in the inhibition of bradykinin releaseInfo
- Publication number
- IL145894A0 IL145894A0 IL14589400A IL14589400A IL145894A0 IL 145894 A0 IL145894 A0 IL 145894A0 IL 14589400 A IL14589400 A IL 14589400A IL 14589400 A IL14589400 A IL 14589400A IL 145894 A0 IL145894 A0 IL 145894A0
- Authority
- IL
- Israel
- Prior art keywords
- hbp
- mammal
- binds
- antagonist
- heparin
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 5
- 101800004538 Bradykinin Proteins 0.000 title abstract 3
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 title abstract 3
- 102100035792 Kininogen-1 Human genes 0.000 title abstract 3
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 title abstract 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title 1
- 229960002897 heparin Drugs 0.000 title 1
- 229920000669 heparin Polymers 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 101710154607 Azurocidin Proteins 0.000 abstract 6
- 241000124008 Mammalia Species 0.000 abstract 5
- 101000793686 Homo sapiens Azurocidin Proteins 0.000 abstract 2
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5064—Endothelial cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
- G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2410/00—Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids
- G01N2410/06—Kallidins; Bradykinins; Related peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13274899P | 1999-04-29 | 1999-04-29 | |
DKPA199900613 | 1999-05-06 | ||
US15738499P | 1999-10-01 | 1999-10-01 | |
DKPA199901402 | 1999-10-01 | ||
PCT/DK2000/000213 WO2000066151A1 (en) | 1999-04-29 | 2000-04-28 | Use of heparin-binding antagonists in the inhibition of bradykinin release |
Publications (1)
Publication Number | Publication Date |
---|---|
IL145894A0 true IL145894A0 (en) | 2002-07-25 |
Family
ID=27439348
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14589400A IL145894A0 (en) | 1999-04-29 | 2000-04-28 | Use of heparin-binding antagonists in the inhibition of bradykinin release |
IL145894A IL145894A (en) | 1999-04-29 | 2001-10-11 | Use of heparin-binding antagonists in the inhibition of bradykinin release |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL145894A IL145894A (en) | 1999-04-29 | 2001-10-11 | Use of heparin-binding antagonists in the inhibition of bradykinin release |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1178821B1 (de) |
JP (1) | JP2002543147A (de) |
CN (2) | CN1349410A (de) |
AT (1) | ATE312622T1 (de) |
AU (2) | AU781734B2 (de) |
CA (1) | CA2370587A1 (de) |
DE (1) | DE60024809D1 (de) |
IL (2) | IL145894A0 (de) |
WO (1) | WO2000066151A1 (de) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003082326A1 (en) * | 2002-03-28 | 2003-10-09 | Hansa Medical Research Aktiebolag | Use of aprotinin for treating wounds and inflammation |
WO2003087134A2 (en) | 2002-04-12 | 2003-10-23 | Schering Corporation | G-protein coupled receptor ligands and methods |
WO2003103475A2 (en) | 2002-06-07 | 2003-12-18 | Dyax Corp. | Prevention and reduction of blood loss |
US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
US20050042213A1 (en) * | 2003-08-14 | 2005-02-24 | Insight Biopharmaceuticals Ltd. | Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof |
US20070269437A1 (en) * | 2003-09-19 | 2007-11-22 | Leukotech A/S | Pro-Inflammatory and Anti-Inflammatory Antibodies Against the Heparin-Binding Protein (Hbp) |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
WO2008077478A1 (en) * | 2006-12-22 | 2008-07-03 | Bayer Schering Pharma Aktiengesellschaft | Preparation and use of variants of the kunitz domain 2 of the human placental bikunin gene |
CN108929374B (zh) * | 2017-05-23 | 2021-08-27 | 福建亿彤生物科技有限公司 | 人hbp抗原表位肽、抗原、抗体、应用及试剂盒 |
JP7395479B2 (ja) * | 2018-01-05 | 2023-12-11 | ノヴォ ノルディスク アー/エス | 免疫抑制なしにil-6媒介性炎症を処置する方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993005396A1 (en) * | 1991-09-12 | 1993-03-18 | Novo Nordisk A/S | A method of screening for inhibitors of heparin-binding protein |
US5356873A (en) * | 1992-11-05 | 1994-10-18 | Clintec Nutrition Co. | Method for providing nutritional requirements to patients having a chronic inflammation reaction |
CN1099462C (zh) * | 1995-03-09 | 2003-01-22 | 洛伊科泰克有限公司 | 药用组合物 |
US5786328A (en) * | 1995-06-05 | 1998-07-28 | Genentech, Inc. | Use of kunitz type plasma kallikrein inhibitors |
US5780265A (en) * | 1995-06-05 | 1998-07-14 | Genentech, Inc. | Kunitz type plasma kallikrein inhibitors |
-
2000
- 2000-04-28 AU AU42860/00A patent/AU781734B2/en not_active Ceased
- 2000-04-28 IL IL14589400A patent/IL145894A0/xx unknown
- 2000-04-28 CN CN00806871A patent/CN1349410A/zh active Pending
- 2000-04-28 EP EP00922472A patent/EP1178821B1/de not_active Expired - Lifetime
- 2000-04-28 AT AT00922472T patent/ATE312622T1/de not_active IP Right Cessation
- 2000-04-28 CA CA002370587A patent/CA2370587A1/en not_active Abandoned
- 2000-04-28 DE DE60024809T patent/DE60024809D1/de not_active Expired - Lifetime
- 2000-04-28 JP JP2000615035A patent/JP2002543147A/ja active Pending
- 2000-04-28 WO PCT/DK2000/000213 patent/WO2000066151A1/en active IP Right Grant
- 2000-04-28 CN CNA2004100080286A patent/CN1550235A/zh active Pending
-
2001
- 2001-10-11 IL IL145894A patent/IL145894A/en not_active IP Right Cessation
-
2005
- 2005-08-23 AU AU2005203787A patent/AU2005203787A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE60024809D1 (de) | 2006-01-19 |
CN1349410A (zh) | 2002-05-15 |
EP1178821A1 (de) | 2002-02-13 |
ATE312622T1 (de) | 2005-12-15 |
EP1178821B1 (de) | 2005-12-14 |
CA2370587A1 (en) | 2000-11-09 |
JP2002543147A (ja) | 2002-12-17 |
AU4286000A (en) | 2000-11-17 |
CN1550235A (zh) | 2004-12-01 |
WO2000066151A1 (en) | 2000-11-09 |
AU781734B2 (en) | 2005-06-09 |
IL145894A (en) | 2009-07-20 |
AU2005203787A1 (en) | 2005-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA02000419A (es) | Bloqueo de la respuesta inmune a un antigeno extrano utilizando un antagonista que se enlaza a cd20. | |
HK1134303A1 (en) | Fab fragment libraries and methods for their use fab | |
MY145191A (en) | Human antibodies that bind human il-12 and methods for producing | |
IL145894A0 (en) | Use of heparin-binding antagonists in the inhibition of bradykinin release | |
BR0207977A (pt) | Métodos de combinação de inibição de crescimento tumoral com um antagonista de receptor de fator de crescimento endotelial | |
NZ337413A (en) | Antibodies that bind to Prostate Stem Cell Antigen (PSCA) to treat prostate cancer. | |
WO2002058717A3 (en) | Methods for treating rheumatoid arthritis using il-17 antagonists | |
NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
DK0536275T3 (da) | Tumorvækstinhibitorer udledt fra væv, fremgangsmåde til deres fremstilling samt anvendelse heraf | |
EA200100822A1 (ru) | Baff, относящиеся к нему блокирующие агенты и их применение в стимуляции и ингибировании b-клеток и иммуноглобулинов в иммунных реакциях | |
HK1074634A1 (en) | Internalizing antibodies specific for the raag10 cell surface target | |
TW200509930A (en) | Methods and compositions for treating rheumatoid arthritis | |
NZ607886A (en) | Nogo receptor binding protein | |
MA44234B1 (fr) | Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3 | |
WO2003087340A3 (en) | Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof | |
ES2216630T3 (es) | Metodos de tratar la hipertension dependiente de la sal. | |
BR0314369A (pt) | Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado | |
NO964015L (no) | Fremgangsmåte for påvisning av kalpain-aktivering og identifisering av kalpain-inhibitorer | |
MX2022002636A (es) | Tratamiento de la enfermedad o trastorno hepatico que comprende los antagonistas del receptor de actrii. | |
TR200103432T2 (tr) | Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı. | |
NO20013459D0 (no) | Anvendelse av agiotensin II reseptorantagonister ved behandling av akutt myokardinfarkt | |
FR2778744B1 (fr) | Dosage immunologique de la chromogranine a humaine (cga) anticorps, reactifs et trousses utilisables pour ce dosage | |
TR199901648T2 (xx) | Laminin'in nidojen domenine ba�lanan antikorlar�n �retilmesi ve kullan�m�. | |
IL129236A0 (en) | Monoclonal antibodies against a human act and serine protease complex | |
MXPA03001331A (es) | Metodos y moleculas utiles para identificar moleculas que se enlazan alfa-1 y para determinar la ocupacion del receptor. |